Company research
Atrium Therapeutics, Inc.
CIK 2093101Updated Nov 14, 2026
SecurityRNA · NASDAQ · equity
RNA price & chart
Loading TradingView…
NASDAQ:RNA on TradingView ↗About the company
Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. The Company’s proprietary technology - designed at Avidity Biosciences, Inc. - combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides and is designed to selectively target the underlying drivers of genetically driven cardiac diseases through targeted, non-viral delivery of small interfering RNA (siRNA). This approach builds upon learnings from demonstrated delivery to skeletal muscle and applies it for efficient delivery to the heart, with the potential to overcome challenges associated with non-specific tissue delivery. The Company’s pipeline includes ATR 1072 for PRKAG2 syndrome, ATR 1086 for PLN (phospholamban) cardiomyopathy and two undisclosed research targets in rare cardiomyopathies.
In the news
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBHC, RNA, NEW, and TWO News provided by Monteverde & Associates PC Jan 30, 2026, 22:46 ET Share this article Share to X Share this article Share to X NEW YORK , Jan. 30, 2026 /PRNewswire/ -- Class Action Attorney Juan ↗
Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights News provided by Halper Sadeh LLP Dec 01, 2025, 18:59 ET Share this article Share to X Share this article Share to X Shareholders should contact the firm immediately as there may be limited tim ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Other Events
Items 8.01, 9.01
Other Events
Items 8.01
Show 5 more recent filings
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Other Events
Items 1.01, 3.02, 8.01, 9.01
4 filing
4 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Filing attachments
d692180dex991.htm · 8-K · 2026-11-12
Exhibit 99.1 Atrium Therapeutics Reports Third Quarter 2026 Financial Results - First patient dosed with ATR 1072 in the Corventis ™ Phase 1/2 clinical trial in PRKAG2 syndrome - - Nonclinical data showed ATR 1072 reversed cardiac glycogen accumulation and improved features of PRKAG2 syndrome - - Pro-forma cash balance at the end of September 2026 was $293.6 million with anticipated cash runway through 2028 - SAN DIEGO, November 12, 2026 / PRNewswire/ - Atrium Therapeutics, Inc. (Nasdaq: RN…
Read attachment ↗d70523dex991.htm · 8-K · 2026-11-02
Exhibit 99.1 Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026 - ATR 1072 impacted key characteristics of PRKAG2 syndrome, including accumulation of cardiac glycogen and cardiac hypertrophy - - Data further reinforce scientific rationale for ATR 1072 targeting the root cause of PRKAG2 syndrome - - Poster presentation November 6 at 5:30 p.m. CT - SAN DIEGO, Nov. 2, 2026 - Atrium T…
Read attachment ↗d70523dex992.htm · 8-K · 2026-11-02
Exhibit 99.2 Atrium Therapeutics 2 November 2026 RNA L I S T E D www.atriumtherapeutics.com NASDAQ 1 Forward-Looking Statements Forward - Looking Statements FORWARD LOOKING STATEMENTS AND OTHER INFORMATION: Certain statements in this Presentation may constitute “forward -looking statem ents” for purposes of the federal securities laws. Our forward -looking statements include, but are not limited to, statements regarding our future results of operations and financial position, including our exp …
Read attachment ↗d134020dex991.htm · 8-K · 2026-10-27
Exhibit 99.1 Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome - Global Phase 1/2 trial will evaluate ATR 1072 in approximately 37 participants - - Initial proof of concept data expected in second half of 2027 - SAN DIEGO, Oct. 27, 2026 - Atrium Therapeutics, Inc. (Nasdaq: RNA) (the “Company”), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, tod…
Read attachment ↗d25901dex41.htm · 8-K · 2026-10-08
Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II) SUCH SECURITIES MAY BE SOLD PURSUANT TO R…
Read attachment ↗d25901dex991.htm · 8-K · 2026-10-08
Exhibit 99.1 Atrium Therapeutics Announces $50 Million Private Placement SAN DIEGO, October 8, 2026 - Atrium Therapeutics, Inc. (Nasdaq: RNA) (“Atrium” or the “Company”), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that it has entered into a securities purchase agreement (the “purchase agreement”) with a group of leading institutional investors for a private placement financing (the “private placement”). The p…
Read attachment ↗